Altaris to Acquire Simulations Plus for $375M, Combining with CCG

Event summary

  • Simulations Plus to be acquired by Altaris for $375M in an all-cash transaction.
  • Deal includes a 26% premium over Simulations Plus' 60-day volume-weighted average price.
  • Post-acquisition, Simulations Plus will be combined with Altaris' portfolio company Chemical Computing Group (CCG).
  • Transaction expected to close in Q4 2026, pending shareholder and regulatory approvals.
  • Simulations Plus will become a privately held subsidiary of Altaris, delisting from Nasdaq.

The big picture

The acquisition reflects the growing trend of consolidation in the biopharma software sector, driven by the shift towards AI-driven, cloud-based platforms. Altaris, with $9B in AUM, is positioning itself to build a leading player in model-informed drug development by combining Simulations Plus with its existing portfolio company, Chemical Computing Group. The deal underscores the increasing importance of software and services in accelerating drug discovery and development.

What we're watching

Integration Strategy
How Altaris will merge Simulations Plus with Chemical Computing Group to create a more comprehensive AI-driven drug development platform.
Market Positioning
Whether the combined entity can better compete against larger players in the biopharma software space.
Execution Risk
The pace at which Altaris can close the deal and integrate the two companies without disrupting ongoing operations.

Related topics

Acquisition Merger